Last close As at 05/08/2026
GBP0.96
▲ 0.05 (0.05%)
Market capitalisation
GBP2,481m
Research: Real Estate
Primary Health Properties’ (PHP’s) H124 results show continuing earnings and dividend growth, driven by rental income and underpinned by a low cost ratio and significantly fixed borrowing costs. With open market rental growth, covering two-thirds of rent roll, accelerating further, we forecast this to continue through FY26, which would mark 30 years of unbroken dividend growth.
Primary Health Properties |
Continuing dividend growth |
H124 results |
Real estate |
24 July 2024 |
Share price performance
Business description
Next event
Analyst
Primary Health Properties is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||
Primary Health Properties’ (PHP’s) H124 results show continuing earnings and dividend growth, driven by rental income and underpinned by a low cost ratio and significantly fixed borrowing costs. With open market rental growth, covering two-thirds of rent roll, accelerating further, we forecast this to continue through FY26, which would mark 30 years of unbroken dividend growth.
Year end |
Net rental income (£m) |
Adjusted earnings* (£m) |
Adjusted EPS** (p) |
NAV per share*** (p) |
DPS |
P/NAV |
Yield |
12/22 |
141.5 |
88.7 |
6.6 |
112.6 |
6.50 |
0.83 |
7.0 |
12/23 |
151.0 |
90.7 |
6.8 |
108.0 |
6.70 |
0.87 |
7.2 |
12/24e |
154.5 |
91.9 |
6.9 |
105.2 |
6.90 |
0.89 |
7.4 |
12/25e |
157.3 |
94.2 |
7.0 |
107.3 |
7.00 |
0.87 |
7.5 |
Note: *Excludes valuation movements, amortisation of fair value adjustment to acquired debt and other exceptional items. **Non-diluted. ***Defined as adjusted EPRA net tangible assets (NTA) excluding fair value of derivative interest rate contracts and convertible bond, deferred tax and fair value adjustment on acquired debt.
Rental growth underpins further progress
Characteristically, H124 results were in line with market expectations, with earnings driven by organic rent growth and dividends (+3% y-o-y) fully covered by adjusted earnings. NAV was 3% lower, with rental growth only partly offsetting yield widening. There is no material change to our income earnings forecasts, which show rental growth, combined with one of the lowest cost ratios in the sector and 96% of debt costs fixed/hedged, driving further growth in fully covered DPS through FY26. Forecast NAV is lower but we expect yields to stabilise, such that rent growth drives NAV gains in future. We assume no benefit from acquisitions, which should look more attractive as interest rates fall and rents increase. For the new developments needed to modernise the healthcare estate to be viable, the rents need to increase 20–30%. This was effectively achieved on one new scheme that commenced in H1, through a capital contribution from the local authorities.
Well-placed to support healthcare reform
The long-term need for primary healthcare facilities is driven by demographic trends and is relatively unaffected by economic conditions. In both the UK and Ireland, populations are growing and ageing, with more complex healthcare needs. Increased use of online and telephone appointments, particularly for frontline triage, has done nothing to reduce the need for modern, integrated, local primary healthcare facilities. Not only will these better serve patients with an extended range of procedures, available locally, they will reduce pressures on the hospitals and support the NHS to reduce the treatment backlog. PHP is well-placed to help meet this need for investment and signals that it will remain the focus of its strategy.
Valuation: Visible income growth
Visible, secure and growing income is the core of the PHP investment case. Leases are long and substantially upward-only, 89% backed directly or indirectly by government bodies, with little exposure to the economic cycle or fluctuations in occupancy. The prospective yield of more than 7% contrasts with the UK 10-year government bond yield of a little over 4%.
Rent growth drives earnings and supports valuations
PHP’s H124 adjusted earnings1 increased by £0.4m or 0.9% to £46.3m compared with H123 (£45.9m). The increase in the period reflects the improving organic rental growth from rent reviews and asset management projects in both FY23 and H124, along with an increased contribution from PHP Axis2 (the Irish property management business acquired in January 2023) and slightly lower administrative costs.3 These were partly offset by increased interest costs on the small proportion of borrowings exposed to interest risk fluctuations. H124 DPS of 3.5p (+3.0%) was fully covered by adjusted EPS.
1 Adjusted earnings and adjusted NTA are EPRA earnings and EPRA NTA, excluding the impact of fair value adjustments to long-term fixed rate debt acquired on the 2019 merger with MedicX. The negative mark to market adjustment (net of amortisation) is excluded from adjusted NTA and the positive, non-cash impact of amortisation on reported finance expense is similarly excluded. A reconciliation is shown in the financial summary (Exhibit 7).
2 The PHP Axis contribution is shown after administrative expenses.
3 Unlike the statutory accounts, administrative expenses are shown excluding costs relating to PHP Axis.
Exhibit 1: Summary of adjusted financial performance measures
£m unless stated otherwise |
H124 |
H123 |
H124/H123 |
2023 |
Net rental income |
76.2 |
75.5 |
0.9% |
149.3 |
Axis contribution |
0.7 |
0.5 |
1.1 |
|
Administrative expenses |
(5.9) |
(6.1) |
-3.3% |
(11.6) |
Net finance expense |
(24.7) |
(24.0) |
2.9% |
(48.1) |
Adjusted earnings* |
46.3 |
45.9 |
0.9% |
90.7 |
EPRA cost ratio |
10.9% |
10.1% |
10.7% |
|
Adjusted EPS (p) |
3.5 |
3.4 |
0.9% |
6.8 |
DPS (p) |
3.5 |
3.4 |
3.0% |
6.7 |
DPS cover (x)** |
1.0 |
1.0 |
1.0 |
|
Adjusted NTA per share (p)*** |
105.0 |
111.1 |
108.0 |
|
Loan to value ratio (LTV) |
48.0% |
45.6% |
47.0% |
Source: PHP data, Edison Investment Research. Note: *Adjusted earnings excludes valuation movements, amortisation of acquired fixed-rate debt revaluation and other exceptional items. **Dividend cover is adjusted earnings as a percentage of dividends declared. ***Adjusted net tangible assets (NTA) per share excludes fair value movements in derivative interest rate contracts and convertible bonds, acquired fixed-rate debt revaluation and deferred tax.
Adjusted net tangible assets (NTA) per share was 3.0p, or 2.9%, lower than at end-FY23 reflecting a property revaluation deficit of £40.0m. This comprised the negative impact of yield widening (£73m), partly offset by gains arising from rental growth and asset management (£33m). The endperiod EPRA net initial yield was 5.18% (end-FY23: 5.05%), with a reversionary yield of 5.5% (endFY23: 5.4%). PHP believes that yield expansion is close to an end and that values should start to stabilise in the remainder of 2024 and 2025, with continuing rental growth offsetting any further widening of yields. It notes the dearth of recent market transactions, leaving valuers significantly reliant on sentiment to arrive at fair values, and believes that further significant reductions in primary care values are likely to be limited, with the stronger rental growth outlook and the expectation of interest rate reductions providing support.
The balance sheet remains strong and liquid, with the cost of 96% of drawn debt fixed or hedged, and more than £300m of undrawn headroom.
No change to forecast earnings and DPS growth
There is no change to our forecasts for growth in FY24 and FY25 adjusted earnings and fully covered DPS. We expect further growth in fully covered DPS in FY26, forecast for the first time. The growth in operating profit is driven by increased rental income, primarily organic but also benefiting from development completions, with further improvement in the already low EPRA cost ratio. PHP expects to save £1m pa from FY25 as a result of staff reductions.
Our forecasts allow for some additional moderate property yield widening (to c 5.35% vs 5.18% at end-H124), more than offset rental growth in FY25 and FY26, with valuation gains generating growth in NAV and a modest reduction in the loan to value ratio (LTV).
Exhibit 2: Summary of forecasts
Actual |
Revised forecast |
Previous forecast |
Growth |
||||||
£m unless stated otherwise |
FY23 |
2024e |
2025e |
2026e |
2024e |
2025e |
2024e |
2025e |
2026e |
Net rental income excluding PHP Axis |
149.4 |
152.7 |
155.8 |
159.9 |
153.1 |
156.6 |
2.2% |
2.1% |
2.6% |
PHP Axis net contribution |
1.1 |
1.8 |
1.4 |
1.5 |
1.2 |
1.3 |
63.6% |
-19.9% |
2.0% |
Administrative expenses |
(11.8) |
(12.4) |
(12.1) |
(12.5) |
(11.7) |
(12.0) |
4.7% |
-2.4% |
3.7% |
Operating profit |
138.7 |
142.1 |
145.2 |
148.9 |
142.6 |
145.9 |
2.5% |
2.2% |
2.5% |
Net financing costs |
(48.0) |
(50.2) |
(51.0) |
(54.4) |
(50.2) |
(52.5) |
|||
Adjusted earnings |
90.7 |
91.9 |
94.2 |
94.5 |
92.4 |
93.3 |
1.3% |
2.5% |
0.3% |
EPRA cost ratio |
10.7% |
10.8% |
10.1% |
10.1% |
10.7% |
10.6% |
|||
Adjusted EPS (p) |
6.8 |
6.9 |
7.0 |
7.1 |
6.9 |
7.0 |
1.3% |
2.5% |
0.3% |
DPS (p) |
6.7 |
6.9 |
7.0 |
7.1 |
6.9 |
7.0 |
3.0% |
1.4% |
1.4% |
Dividend cover (x) |
1.01 |
1.00 |
1.01 |
1.00 |
1.00 |
1.00 |
|||
Adjusted EPRA NTA per share (p) |
108.0 |
105.2 |
107.3 |
110.3 |
107.1 |
109.4 |
-2.6% |
2.0% |
2.8% |
LTV |
47.0% |
48.0% |
47.5% |
46.9% |
47.8% |
47.6% |
|||
Source: Edison Investment Research forecasts, PHP FY23 data
Accelerating market rent uplifts support the outlook
Organic rental growth is driving earnings growth and we expect this to continue as market rents accelerate. Annualised rent roll increased by £1.8m in H124, to £152.6m, including £1.6m from rent reviews and £0.2m from asset management projects. Acquisitions (see below) added £0.5m but this was offset by FX translation movements in respect of the Irish portfolio and lease surrenders and voids. Occupancy of 99.2% was temporarily affected by the insolvency of LloydsPharmacy at three units in the UK (co-located with primary health facilities) and the surrender of two pharmacy leases in Ireland, where the space is to be re-let to the HSE as part of an asset management initiative.
The annualised rent increases secured on completed reviews have picked up very significantly over the past three years. The continued acceleration of open market rent reviews in H124 is highly encouraging even though the overall achieved increase of 3.2% was lower than the 4.0% average annual uplift in 2023, as the impact of inflation linked uplifts waned.
|
Exhibit 3: Rental growth is continuing to accelerate |
|
Source: PHP data, Edison Investment Research
Open market reviews apply to 68% of rent roll and are key to sustaining organic rental growth. After many years of very modest uplifts, high levels of land and building cost inflation, particularly in the past couple of years, are increasingly being recognised but there is much further to go. Open market rents are typically reviewed every three years, but it can take much longer for these to settle. At end-H124, rent reviews on £87m of rents were outstanding. Around half the outstanding reviews are in the process of being settled, with the potential to lift rents by £2.1m or 4.8% versus the existing level. The balance of outstanding reviews will be actioned when there is further comparative evidence available to support the expected level of market rent. All awards need to be agreed with the district valuer and the evidence to support uplifts comes from the completion of historical rent reviews and the rents set on delivery of new properties into the sector. NHS initiatives to modernise the primary care estate will result in previously agreed rental values having to be renegotiated to make a number of these projects viable in the current economic environment.
Exhibit 4: Annualised rental uplifts on completed rent reviews in the period
H124 |
2023 |
2022 |
2021 |
2020 |
|
UK – open market |
2.1% |
1.8% |
1.5% |
1.5% |
1.3% |
UK – indexed |
4.8% |
8.4% |
7.4% |
2.8% |
2.3% |
UK – fixed |
2.8% |
2.7% |
3.1% |
2.9% |
2.7% |
Total UK |
3.2% |
4.0% |
3.4% |
1.7% |
1.8% |
Ireland – indexed |
4.6% |
3.3% |
2.6% |
0.8% |
1.1% |
Total annualised increase |
3.2% |
4.0% |
3.4% |
1.7% |
1.8% |
Source: PHP
The balance of UK rents are linked to UK inflation (27%) or have fixed uplifts (5%). Irish rents (c 9% of the total) are linked to Irish CPI and are reviewed every five years.
The improving rental growth outlook is reflected in the independent valuers’ assessment of estimated rental values (ERV) of the portfolio, which increased by 1.7% in H124. The portfolio reversionary yield is 5.5% compared with the EPRA net initial yield of 5.23%.
Highly selective external investment stance
PHP adopted a cautious approach to investment activity as acquisition yields tightened, this continued as interest rates climbed, and remains the case until the economic and interest rate environment become clearer. During H124, it ‘opportunistically’ acquired a completed health centre at Basingstoke for a total consideration of £4.5m and commenced work on its second development scheme at South Kilburn, London. The scheme was made viable by a capital contribution from the commissioning Integrated Care Board and local authority, each contributing £0.5m to the overall development cost. By reducing PHP’s share of the cost, this equates to a 26% uplift in the rent originally set by the district valuer.
More generally, PHP continues to pause direct development activity and estimates that to compensate for much higher costs, to make new development economically viable and bring forward schemes that are much needed by the NHS, agreed rents need to be 20–30% higher.
Ireland remains PHP’s preferred area of future investment activity, with similar market dynamics to the UK from a lower cost of capital and higher property yields. Over the medium term, the company targets an increase in the Irish share of the portfolio from the current 9% to c 15%. However, PHP’s most immediate pipeline of external investment opportunities in legal due diligence continues to be focused predominantly on existing portfolio asset management projects. These create value by increasing rents and extending lease lengths. There are currently 23 projects in legal due diligence with an aggregate investment requirement of c £15.3m, expected to generate an additional £0.7m pa of rental income and extending the weighted average unexpired lease term on those premises back to an average of 19 years.
The new UK government is committed to NHS investment
The UK commitment to NHS reform and investment has been reiterated by the new government, particularly a continuation of the shift of services out of hospitals and into the community. It recognises the need for a reform of primary healthcare and seeks to provide enhanced patient access to services and earlier diagnosis of progressive health conditions, but this will be challenging to achieve and will require significant investment. Driven by an increasing and ageing population, there is constantly growing demand for healthcare services, while existing facilities face capacity constraints. The extent of the NHS backlog also remains a significant concern, with the number of patients waiting for treatment reaching record highs and hospitals struggling to meet objectives. All these factors make more urgent the need for improved and increased primary healthcare infrastructure, with approximately one-third of the UK’s current primary care estate in need of modernisation or replacement.
PHP is very well placed to help meet the need for investment but, for it to be economically viable, rents must increase materially.
Strong, flexible balance sheet, with rate protection
PHP has a strong balance sheet. Debt facilities are well spread by lending source and maturity, with an average maturity of more than six years. Of the drawn debt, 96% is fixed rate or hedged, with an average rate of 3.3%. Allowing for capital commitments, it has more than £300m of undrawn headroom.
The LTV ratio increased marginally to 48.0% during H124, due to the property valuation movements, but it sits comfortably within the company’s target range of 40–50%. Although this is above the LTV range for more mainstream listed UK commercial property investors, it needs to be seen in the context of the exceptional strength of the tenant covenant, the essential nature of the assets and long leases with upwards-only4 rent reviews. Net debt/EBITDA is more than 9x. It would take a more than 30% decline in portfolio value, or an implied 8.0% net initial yield, to challenge covenant headroom. Rightly in our view, PHP has reiterated its comfort with its balance sheet structure and, for the avoidance of doubt, confirmed that it has no plans to reduce borrowing by raising equity.
4 It is possible for Irish rents to be negatively indexed to inflation, but this seems a remote prospect.
Terms have been agreed to extend and increase existing revolving credit facilities that mature in 2025. Once completed, the new facilities will provide sufficient headroom to repay both the £150m convertible bond and £70m variable rate bonds that mature in 2025.
Low volatility, income-led returns
Progressive, fully covered DPS
Stable and growing dividends are central to PHP’s business model and the investment case. PHP is already in its 28th year of unbroken DPS growth and the company comments that this is set to continue as the new UK government commits to increased investment in primary and community care.
For the current (FY24) year, PHP targets annual DPS of 6.9p, in four equal payments, three of which have already been paid or declared. We forecast dividends of 7.0p in FY25 and 7.1p in FY26.
|
Exhibit 5: Now in the 28th year of unbroken dividend growth |
|
|
Source: PHP data |
Over 10 years to H124, PHP has generated an average accounting total return/ EPRA NTA total return5 of 8.0% pa. Dividends paid have accounted for two-thirds of the total.
5 The change in EPRA NTA plus dividends paid (but not assuming reinvestment).
|
Exhibit 6: 10-year income and capital returns |
|
|
Source: PHP data, Edison Investment Research. Note: *H214 and H124 are annualised rates. |
Exhibit 7: Financial summary
Year end 31 December (£m) |
2020 |
2021 |
2022 |
2023 |
2024e |
2025e |
2026e |
PROFIT & LOSS |
|||||||
Net rental income |
131.2 |
136.7 |
141.5 |
149.9 |
152.7 |
155.8 |
159.9 |
PHP Axis net contribution |
0.0 |
0.0 |
0.0 |
1.1 |
1.8 |
1.4 |
1.5 |
Net property income |
131.2 |
136.7 |
141.5 |
151.0 |
154.5 |
157.3 |
161.4 |
Administrative expenses |
(13.2) |
(10.5) |
(9.6) |
(13.7) |
(13.4) |
(13.1) |
(13.5) |
Operating profit before revaluation movements and non-recurring items |
118.0 |
126.2 |
131.9 |
137.3 |
141.1 |
144.2 |
147.9 |
Net realised and unrealised portfolio gains/(losses) |
51.4 |
110.5 |
(61.5) |
(53.0) |
(40.0) |
30.0 |
40.0 |
Exceptional items related to corporate acquisition |
0.0 |
(37.0) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
Operating profit |
169.4 |
199.7 |
70.4 |
84.3 |
101.1 |
174.2 |
187.9 |
Finance income |
1.2 |
0.8 |
0.9 |
0.2 |
0.0 |
0.0 |
0.0 |
Finance expense |
(43.0) |
(60.5) |
(41.2) |
(45.2) |
(47.2) |
(48.0) |
(51.4) |
Fair value movement on swaps and convertible bond |
(15.2) |
1.6 |
26.8 |
(13.2) |
(4.2) |
(1.4) |
0.0 |
Profit Before Tax |
112.4 |
141.6 |
56.9 |
26.1 |
49.7 |
124.8 |
136.5 |
Tax |
(0.4) |
(1.5) |
(0.6) |
1.2 |
(0.9) |
0.0 |
0.0 |
Profit After Tax |
112.0 |
140.1 |
56.3 |
27.3 |
48.8 |
124.8 |
136.5 |
Adjusted for the following: |
|||||||
Net realised/unrealised gain/(loss) on investment property |
(51.4) |
(110.5) |
61.5 |
53.0 |
40.0 |
(30.0) |
(40.0) |
Fair value gain/(loss) on derivatives & convertible bond |
15.2 |
(1.6) |
(26.8) |
13.2 |
4.2 |
1.4 |
0.0 |
Other adjustments |
0.4 |
26.1 |
0.6 |
0.2 |
1.9 |
1.0 |
1.0 |
EPRA earnings |
76.2 |
62.1 |
91.6 |
93.7 |
94.9 |
97.2 |
97.5 |
Amortisation of fair value adjustment to acquired debt |
(3.1) |
(3.2) |
(2.9) |
(3.0) |
(3.0) |
(3.0) |
(3.0) |
Other non-recurring charges and adjustments |
0.0 |
24.3 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
Adjusted earnings |
73.1 |
83.2 |
88.7 |
90.7 |
91.9 |
94.2 |
94.5 |
Period end number of shares (m) |
1,315.6 |
1,332.9 |
1,336.5 |
1,336.5 |
1,336.5 |
1,336.5 |
1,336.5 |
Average Number of Shares Outstanding (m) |
1,266.4 |
1,330.4 |
1,334.8 |
1,335.7 |
1,336.5 |
1,336.5 |
1,336.5 |
Fully diluted average number of shares outstanding (m) |
1,368.4 |
1,435.8 |
1,443.7 |
1,444.6 |
1,451.7 |
1,451.7 |
1,336.5 |
Basic IFRS EPS (p) |
8.8 |
10.5 |
4.2 |
2.0 |
3.7 |
9.3 |
10.2 |
Adjusted EPS (p) |
5.8 |
6.2 |
6.6 |
6.8 |
6.9 |
7.0 |
7.1 |
Dividend per share (p) |
5.9 |
6.2 |
6.5 |
6.7 |
6.90 |
7.00 |
7.10 |
Dividend cover (x) |
1.0 |
1.0 |
1.0 |
1.0 |
1.0 |
1.0 |
1.0 |
Adjusted EPRA NTA total return |
10.1% |
8.9% |
2.0% |
2.0% |
3.8% |
8.7% |
9.4% |
EPRA cost ratio |
11.9% |
9.3% |
9.9% |
10.7% |
10.8% |
10.1% |
10.1% |
BALANCE SHEET |
|||||||
Non-current assets |
2,576.1 |
2,801.4 |
2,816.3 |
2,786.9 |
2,762.0 |
2,799.0 |
2,845.0 |
Investment properties |
2,576.1 |
2,795.9 |
2,796.3 |
2,779.3 |
2,755.3 |
2,793.3 |
2,840.3 |
Other non-current assets |
0.0 |
5.5 |
20.0 |
7.6 |
6.7 |
5.7 |
4.7 |
Current Assets |
121.0 |
51.7 |
48.2 |
40.0 |
37.7 |
38.3 |
47.0 |
Cash & equivalents |
103.6 |
33.4 |
29.1 |
3.2 |
4.3 |
4.9 |
13.6 |
Other current assets |
17.4 |
18.3 |
19.1 |
36.8 |
33.4 |
33.4 |
33.4 |
Current Liabilities |
(68.1) |
(70.5) |
(64.1) |
(71.2) |
(65.0) |
(65.0) |
(65.0) |
Current borrowing |
(6.4) |
(2.2) |
(2.3) |
(2.4) |
0.0 |
0.0 |
0.0 |
Other current liabilities |
(61.7) |
(68.3) |
(61.8) |
(68.8) |
(65.0) |
(65.0) |
(65.0) |
Non-current liabilities |
(1,214.6) |
(1,282.7) |
(1,318.2) |
(1,331.8) |
(1,352.5) |
(1,358.9) |
(1,371.9) |
Non-current borrowings |
(1,206.5) |
(1,273.0) |
(1,297.1) |
(1,320.9) |
(1,341.3) |
(1,347.7) |
(1,360.7) |
Other non-current liabilities |
(8.1) |
(9.7) |
(21.1) |
(10.9) |
(11.2) |
(11.2) |
(11.2) |
Net Assets |
1,414.4 |
1,499.9 |
1,482.2 |
1,423.9 |
1,382.2 |
1,413.4 |
1,455.1 |
Derivative interest rate swaps |
0.1 |
(4.4) |
(7.1) |
(2.7) |
(2.7) |
(2.7) |
(2.7) |
Change in fair value of convertible bond |
25.0 |
21.6 |
(7.1) |
(2.3) |
(2.8) |
(2.8) |
(2.8) |
Other EPRA adjustments |
45.8 |
38.8 |
36.8 |
26.1 |
29.6 |
26.6 |
25.1 |
Adjusted EPRA net tangible assets (NTA) |
1,485.3 |
1,555.9 |
1,504.8 |
1,445.0 |
1,406.3 |
1,434.5 |
1,474.7 |
IFRS NAV per share (p) |
107.5 |
112.5 |
110.9 |
106.5 |
103.4 |
105.8 |
108.9 |
Adjusted EPRA NTA per share (p) |
112.9 |
116.7 |
112.6 |
108.1 |
105.2 |
107.3 |
110.3 |
CASH FLOW |
|||||||
Operating Cash Flow |
118.9 |
140.4 |
117.6 |
133.6 |
138.5 |
145.2 |
148.9 |
Net Interest & other financing charges |
(65.9) |
(46.6) |
(42.4) |
(47.1) |
(47.7) |
(48.0) |
(51.4) |
Tax |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
Acquisitions/disposals |
(102.8) |
(129.3) |
(74.8) |
(39.5) |
(20.6) |
(8.0) |
(7.0) |
Net proceeds from issue of shares |
136.8 |
(0.1) |
(0.1) |
0.0 |
0.0 |
0.0 |
0.0 |
Debt drawn/(repaid) |
(58.4) |
82.8 |
48.8 |
23.6 |
23.1 |
5.0 |
13.0 |
Equity dividends paid (net of scrip) |
(69.1) |
(74.4) |
(81.6) |
(89.5) |
(92.2) |
(93.6) |
(94.9) |
Other cash movements and FX |
1.6 |
(43.6) |
28.9 |
(7.0) |
0.0 |
0.0 |
0.0 |
Net change in cash |
(39.5) |
(70.2) |
(4.3) |
(25.9) |
1.1 |
0.7 |
8.6 |
Opening cash & equivalents |
143.1 |
103.6 |
33.4 |
29.1 |
3.2 |
4.3 |
4.9 |
Closing net cash & equivalents |
103.6 |
33.4 |
29.1 |
3.2 |
4.3 |
4.9 |
13.6 |
Debt as per balance sheet |
(1,212.9) |
(1,275.2) |
(1,299.4) |
(1,323.3) |
(1,341.3) |
(1,347.7) |
(1,360.7) |
Convertible bond fair value adjustment |
25.0 |
21.6 |
(7.1) |
(2.3) |
(1.4) |
0.0 |
0.0 |
Unamortised borrowing costs |
(13.8) |
(13.7) |
(15.3) |
(12.7) |
(10.4) |
(7.4) |
(5.9) |
Fair value of acquired debt |
42.4 |
34.4 |
31.4 |
28.4 |
25.5 |
22.5 |
21.0 |
Closing net debt/(cash) |
(1,055.7) |
(1,199.5) |
(1,261.3) |
(1,306.7) |
(1,323.3) |
(1,327.7) |
(1,332.0) |
Net LTV |
41.0% |
42.9% |
45.1% |
47.0% |
48.0% |
47.5% |
46.9% |
Source: PHP historical data, Edison Investment Research forecasts
|
|
Research: Healthcare
Mendus has announced a collaboration with Institut Bergonié, an established comprehensive cancer centre in France, to test ilixadencel in soft tissue sarcomas (STS) as part of an ongoing Phase I/II basket trial (REGOMUNE). The trial is a multi-centre, prospective open-label study assessing the combination of regorafenib (a tyrosine kinase inhibitor) and avelumab (an immune checkpoint inhibitor) in various solid tumours. Ilixadencel will be evaluated along with a combination in one of the treatment arms and the trial will involve up to 43 STS patients. The trial is sponsored by Institut Bergonié and Mendus will supply ilixadencel to the STS cohort (regorafenib and avelumab will be supplied by Bayer and Merck KGaA, respectively). Management expects trial preparations for the ilixadencel arm to be completed in H224, with the first patient data expected in H126. We anticipate that trial readouts will influence the clinical path forward.